UK national audit of extracorporeal photopheresis in CTCL.

Abstract

We performed a national audit of extracorporeal photopheresis (ECP) in cutaneous T-cell lymphoma (CTCL) to gather information on number of treatment cycles, treatment duration and reason for stopping. UK Consensus Guidelines and European ECP Guidelines recommend that ECP can be considered for first-line treatment for erythrodermic CTCL patients with blood involvement [1,2,3]. Publications have shown effectiveness of ECP in early-stage MF, stage IA-IIA [4,5] and ECP is listed as a systemic treatment option in refractory early-stage MF in the National Comprehensive Cancer Network Guidelines [6]. This article is protected by copyright. All rights reserved.